Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dexpanthenol→

Dexpanthenol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
81-13-0
Molecular formula
C9H19NO4
Molecular weight
205.25 g/mol
Drug class
Alcoholic analogue of D-pantothenic acid (provitamin B5)topical skin protectant and wound-healing agent
Mechanism of action
Converted in tissues to pantothenic acid, a precursor of coenzyme A required for acetylation reactions and lipid metabolism. The exact clinical mechanism of topical skin effects is not fully established; it supports epithelial hydration and repair.
Indications / reported uses
  • Topical relief of dry, irritated or superficially damaged skin and support of skin-barrier repair; specific indications vary by cream, ointment, spray or other formulation

Sources: NCI Drug Dictionary — Dexpanthenol cream · NCI Drug Dictionary — Dexpanthenol mouthwash · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dexpanthenol Environmental Risk Assessment (ERA) (the Dexpanthenol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.